Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
Drugs not commonly considered to be cardioactive agents have been reported to cause prolongation of the corrected QT interval with resultant torsades de pointes or ventricular fibrillation. We report 4 cases of gatifloxacin-associated cardiac toxicity in patients with known risk factors for this adverse event.
Bertino
Joseph S
JS
Departments of Pharmacy Services and Medicine, Division of Clinical Pharmacology, Bassett Healthcare, Cooperstown, NY, 13326, USA. sbertino@ix.netcom.com
Owens
Robert C
RC
Carnes
Timothy D
TD
Iannini
Paul B
PB
D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects*; D005260:Female; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006321:Heart / Q000187:drug effects; D006801:Humans; D008133:Long QT Syndrome; D008875:Middle Aged; D012307:Risk Factors; D016171:Torsades de Pointes / Q000139:chemically induced*; D014693:Ventricular Fibrillation / Q000139:chemically induced*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin